In vitro and in vivo photosensitizing capabilities of 5-ALA versus Photofrin� in vascular endothelial cells

Chang, Cheng Jen; Sun, Chung Ho; Liaw, Lih‐Huei L.; Berns, Michael W.; Nelson, J. Stuart

doi:10.1002/(sici)1096-9101(1999)24:3<178::aid-lsm2>3.0.co;2-w

Cited by 39 publications

(31 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effective dosage is eventually altered by additional biological factors such as different drug uptake [22][23][24], various tissue optical properties [25], changes in vasculature and perfusion [26,27], and inconsistencies in tissue oxygenation [28], as well as unexpected photophysical and photochemical changes of photosensitizers [29][30][31]. The schematics of the three main dose factors are illustrated in Figure 1a, and the interdependencies of dose factors [32] are summarized in Table 1.…”

Section: Limitation Factors In Pdt Dosimetrymentioning

confidence: 99%

Time-Resolved Fluorescence in Photodynamic Therapy

et al. 2014

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has been used clinically for treating various diseases including malignant tumors. The main advantages of PDT over traditional cancer treatments are attributed to the localized effects of the photochemical reactions by selective illumination, which then generate reactive oxygen species and singlet oxygen molecules that lead to cell death. To date, over-or under-treatment still remains one of the major challenges in PDT due to the lack of robust real-time dose monitoring techniques. Time-resolved fluorescence (TRF) provides fluorescence lifetime profiles of the targeted fluorophores. It has been demonstrated that TRF offers supplementary information in drug-molecular interactions and cell responses compared to steady-state intensity acquisition. Moreover, fluorescence lifetime itself is independent of the light path; thus it overcomes the artifacts given by diffused light propagation and detection geometries. TRF in PDT is an emerging approach, and relevant studies to date are scattered. Therefore, this review mainly focuses on summarizing up-to-date TRF studies in PDT, and the effects of PDT dosimetric factors on the measured TRF parameters. From there, potential gaps for clinical translation are also discussed. OPEN ACCESSPhotonics 2014, 1 531

show abstract

Section: Limitation Factors In Pdt Dosimetrymentioning

confidence: 99%

Time-Resolved Fluorescence in Photodynamic Therapy

et al. 2014

View full text Add to dashboard Cite

show abstract

“…By contrast, in ALA-PDT, damage to tumor vessels that could induce a decrease in blood flow does not occur; although mild damage to vascular endothelial cells can be observed (39,40). It is considered that ALA-PDT exhibits less effects than PDT using Photofrin since ALA-PDT therapy exhibits less effects on tumor vessels and blood flow (39).…”

Section: -------------------------------------------------Table IV Smentioning

confidence: 99%

Synergistic interaction of 5-aminolevulinic acid-based photodynamic therapy with simultaneous hyperthermia in an osteosarcoma tumor model

Yanase¹,

Nomura²,

Matsumura³

et al. 2006

Int J Oncol

View full text Add to dashboard Cite

Abstract. In this study, the effectiveness and mechanism of combination therapy of 5-aminolevulinic acid-based photodynamic therapy (ALA-PDT) with simultaneous hyperthermia (HT) on human-derived osteosarcoma in vivo were examined. A tumor model was prepared by subcutaneously implanting human osteosarcoma into nude mice and local injection of ALA was selected as the administration route. This study demonstrated that both ALA-PDT and the combination of ALA-PDT with HT exhibited significant inhibitory effects on tumor growth. In the group with high total energy, the growth inhibition rates of tumor were 52.3% in ALA-PDT, and 27.3% in ALA-PDT with simultaneous HT (PDT+HT), and the synergetic index was 1.76, demonstrating that the inhibitory effect on tumor growth in ALA-PDT was significantly increased by simultaneous use of HT. In the histological findings, after ALA-PDT, necrosis was observed in the area from the surface to a depth of 2 mm, and only a slight effect was confirmed in deeper layers. On the other hand, after PDT+HT, necrosis was observed in layers even deeper than 2 mm below the surface. Furthermore, based on the immunohistochemical findings of the expression of carbonic anhydrase IX, while weak expression of CAIX was observed after ALA-PDT in an area relatively close to the surface, a positive area extended to the deeper layers after PDT+HT compared with ALA-PDT. In conclusion, PDT+HT demonstrated a significant inhibitory effect on tumor growth of human-derived osteosarcoma, and a synergistic interaction of simultaneous HT. This suggests the possibility that ALA-PDT is useful, not only for the treatment of superficial tumors but also for deep-seated mesenchymal tumors, such as osteosarcoma. Furthermore, the mechanism of the synergistic interaction suggested that ALA-PDT was effective in the deep area of tumors due to the increase of blood flow by mild hyperthermia.

show abstract

“…(e) Power densities have been varied to study PDTinduced oxygen depletion [53,54], tissue response to PDT [37,55] or hyperthermia effects [56]. We have used two values (33 and 100 mW/cm 2 ) and have kept the light dose constant by varying the irradiation time.…”

Section: Choice Of Treatment Variablesmentioning

confidence: 99%

“…The present study is limited to four compounds: sulfonated chloro-aluminum phthalocyanine (AlPcS n ) [14], benzoporphyrin derivative monoacid ring A (BPD-MA) [15,16], lutetium texaphyrin (Lutex) [17][18][19], and aminolevulinic acid (ALA), a precursor of the endogenous sensitizer protoporphyrin IX (PpIX) [20]. In Table 1 Thursday we present some published results of the PDT efficiency, relative to Photofrin, of these selected sensitizers [21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38].…”

Section: Introductionmentioning

confidence: 99%